Your basket is currently empty!
Mastering Immunity Europe 2021
Mastering Immunity Europe 2021

Understand and manage immune responses in any setting
Thursday 25 March, 2021
9:00am GMT / 10:00am CET
Register Today
As targeted immune therapies grow in complexity, understanding and characterizing immune responses has never been more important. Join us at Mastering Immunity Europe 2021 to learn the latest developments in this evolving field. This meeting is a forum to share knowledge, perspectives and discuss solutions to the complex challenges of immunity following the delivery of biologics and other therapies.
Learn from academic and commercial experts as they highlight their discoveries in the context of both desired (in immuno-oncology and vaccines) and unwanted immune responses (i.e. immunogenicity to biotherapeutics or viral vectors). Share information with like-minded scientists from other organizations and explore new opportunities for collaboration. Discover fresh perspectives and novel ideas to combat the challenges in the rapidly changing field of immunology.
2021 Programme
Time GMT | Speaker | Title | |
09:00am | WELCOME | ||
09:10am | ![]() | Dr. Amy Flaxman, University of Oxford | Antibody responses to viral-vectored coronavirus vaccines |
09:35am | ![]() | Dr. Tom Henley, Empyrean Therapeutics | COVID-19 and Potential Future Pandemics: Virus Induced Lymphocytes (VIL) |
10:00am | ![]() | Dr. Alethea Cope, IAVI | Developing Vaccines and Therapeutics for Emerging Infectious Diseases |
10:25am | NETWORKING BREAKOUT ROOMS | ||
11:00am | ![]() | Prof. Daniel Olive IBiSA Cancer Immunomonitoring Platform | Liquid Biopsy using K-Cytof demonstrates a role for Vg9Vd2 T cells as prognostic factor in breast cancer |
11:25am | ![]() | Mr. Edmund Neo, ProImmune | Clinical Immune Monitoring in Gene Therapy, Immuno-Oncology and SARS-CoV-2 Programs |
11:50am | ![]() | Dr. Cynthia Kramer, Leiden University | Generation and reactivity analysis of human recombinant monoclonal antibodies directed against epitopes on HLA-DR |
12:25pm | BREAK FOR LUNCH | ||
13:30pm | ![]() | Dr. Jeremy Fry, ProImmune | An integrated approach to managing immunogenicity risk and drug immune modulation |
13:55pm | ![]() | Dr. Zuben Sauna, FDA | Understanding and navigating the immune responses to CRISPR-associated nuclease Cas9 |
14:20pm | ![]() | Dr. Geoff Hale, mAbsolve | Characterisation of novel antibodies which are completely silenced with respect to Fc |
14:45pm | NETWORKING BREAKOUT ROOMS | ||
15:10pm | ![]() | Dr. Derek Doherty, Trinity College Dublin | CD1d-restricted T cells in patients with oesophageal cancer |
15:35pm | ![]() | Dr. Quirin Hammer, Karolinska Institute | HLA-E-restricted peptides control natural killer cell responses |
16:00pm | Meeting Close |
Mastering Immunity At a Glance
See highlights and feedback from speakers and attendees from Mastering Immunity Europe
Speakers from previous years
Presentations from our meetings are available online free of charge.
Dr. Lea Bartsch, Massachusetts General Hospital | Dr. Inderpal Singh, TEVA Pharmaceuticals | Dr. Zuben Sauna, FDA | Prof. Tao Dong, University of Oxford |
Prof. Arlene Sharpe, Harvard University | Dr. Laurent Malherbe, Eli Lilly | Dr. David Wraith, Apitope | Dr. Priya Sriraman, Celgene |
Dr. Vibha Jawa, Merck | Dr. Rodd Polsky, GSK | Prof. Farzin Farzeneh, Kings College London | Dr. Nina Le Bert Duke NUS |
Dr. Tim Hickling, Roche | Prof. Beatriz Carreno, University of Pennsylvania | Dr. Jochem Gokemeijer, Bristol-Myers Squibb | Dr. Sophie Tourdot, Pfizer |
How will I benefit?

- Be informed of the latest
strategies for preclinical and clinical immune modulation - Quality by Design in drug
development - Case Studies
- Learn the key issues facing
drug developers
Conference Enquiries:
Email: enquiries@proimmune.com
Telephone (toll free): USA & Canada +1 888 505 7765